Theodore Alan Huizenga - 02 Mar 2026 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
SVP, Chief Accounting Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
02 Mar 2026
Net transactions value
-$40,671
Form type
4
Filing time
03 Mar 2026, 18:51:08 UTC
Previous filing
30 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Huizenga Theodore Alan SVP, Chief Accounting Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO /s/ Karah Parschauer, attorney-in-fact 03 Mar 2026 0001603347

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Tax liability $3,462 -148 -0.29% $23.39 50,302 02 Mar 2026 Direct F1
transaction RARE Common Stock Sale $37,210 -1,632 -3.2% $22.80 48,670 02 Mar 2026 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F2 Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.